Download PDF
Dtsch Med Wochenschr 2014; 139(34/35): 1714-1720
DOI: 10.1055/s-0034-1370258
Übersicht | Review article
Pneumologie
© Georg Thieme Verlag KG Stuttgart · New York

Non-CF-Bronchiektasen: Diagnostik und Therapie

Non-cystic fibrosis bronchiectasis: diagnosis and treatment
L. C. Huber
1   Klinik für Pneumologie, UniversitätsSpital Zürich
,
U. Bürgi
1   Klinik für Pneumologie, UniversitätsSpital Zürich
,
M. M. Schuurmans
1   Klinik für Pneumologie, UniversitätsSpital Zürich
,
C. Benden
1   Klinik für Pneumologie, UniversitätsSpital Zürich
› Author Affiliations
Further Information

Publication History

17 December 2013

22 May 2014

Publication Date:
12 August 2014 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Bronchiektasen bezeichnen irreversibel erweiterte Atemwege. Genaue epidemiologische Angaben zur Prävalenz von Bronchiektasen existieren nicht, sie sind aber häufig und werden zunehmend als solche erkannt. Eine Vielzahl von Erkrankungen und Auslöser können zu Bronchiektasen führen, häufig bleibt ihre Ätiologie unklar. Eine chronische pulmonale Infektion mit Pseudomonas aeruginosa ist mit einem schwereren klinischen Verlauf assoziiert und beeinflusst das therapeutische Management. Physiotherapie, mukoaktive Substanzen und Antibiotika sind die Eckpfeiler der Therapie von Bronchiektasen. Einen zunehmenden Stellenwert hat die immunmodulatorische Therapie mit Makroliden. In dieser Übersicht werden notwendige Abklärungen und neueste Entwicklungen hinsichtlich therapeutischer Ansätze bei Non-CF-Bronchiektasen diskutiert.

Abstract

Bronchiectasis is the term used for irreversibly dilated airways. Exact epidemiological information on the frequency of bronchiectasis is not available, but the morphological findings are increasingly detected and the associated syndrome is more frequently diagnosed due to improved imaging techniques and increased awareness among chest physicians. The workup of these patients includes a wide panel of investigations guided by patient history and clinical presentation. Despite thorough evaluation the aetiology frequently remains unclear. Chronic infection with Pseudomonas aeruginosa is associated with a severe course of the disease and its detection has impacts on the therapeutic management. Chest physiotherapy, mucoactive substances and antibiotics are the mainstay of therapy. In this review the evaluation of bronchiectasis and the recent therapeutic insights for non-cystic fibrosis bronchiectasis are discussed.

Schlüsselwörter

Non-CF Bronchiektasen - Abklärung - Keimspektrum - Exazerbationen - Therapie

Keywords

non-CF bronchiectasis - diagnosis - bacteria - exacerbation - therapy
 

  • Literatur

  • 1 Altenburg J, de Graaff CS, Stienstra Y et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA 2013; 309: 1251-1259
    CrossrefPubMedGoogle Scholar
  • 2 Barreto MM, Rafful PP, Rodrigues RS et al. Correlation between computed tomographic and magnetic resonance imaging findings of parenchymal lung diseases. Eur J Radiol 2013; 82: e492-501
    CrossrefPubMedGoogle Scholar
  • 3 Bennett WD. Effect of beta-adrenergic agonists on mucociliary clearance. J Allergy Clin Immunol 2002; 110 (Suppl. 06) S291-297
    CrossrefPubMedGoogle Scholar
  • 4 Binder AM, Adjemian J, Olivier KN et al. Epidemiology of nontuberculous mycobacterial infections and associated chronic macrolide use among persons with cystic fibrosis. Am J Respir Crit Care Med 2013; 188: 807-812
    CrossrefPubMedGoogle Scholar
  • 5 Catherinot E, Roux AL, Vibet MA et al. Inhaled therapies, azithromycin and Mycobacterium abscessus in cystic fibrosis patients. Eur Respir J 2013; 41: 1101-1106
    CrossrefPubMedGoogle Scholar
  • 6 Chalmers JD, Goeminne P, Aliberti S et al. The bronchiectasis severity index. An international derivation and validation study. Am J Respir Crit Care Med 2014; 189: 576-585
    CrossrefPubMedGoogle Scholar
  • 7 Chalmers JD, Smith MP, McHugh BJ et al. Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2012; 186: 657-665
    CrossrefPubMedGoogle Scholar
  • 8 Cole PJ. Inflammation: a two-edged sword--the model of bronchiectasis. Eur J Respir Dis Suppl 1986; 147: 6-15
    PubMedGoogle Scholar
  • 9 Davis SD, Ferkol T. Identifying the origins of cystic fibrosis lung disease. N Engl J Med 2013; 368: 2026-2028
    CrossrefPubMedGoogle Scholar
  • 10 Devaraj A, Wells AU, Meister MG et al. Pulmonary hypertension in patients with bronchiectasis: prognostic significance of CT signs. AJR Am J Roentgenol 2011; 196: 1300-1304
    CrossrefPubMedGoogle Scholar
  • 11 Elkins MR, Robinson M, Rose BR et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006; 354: 229-240
    CrossrefPubMedGoogle Scholar
  • 12 Haworth CS, Foweraker JE, Wilkinson P et al. Inhaled Colistin in Patients with Bronchiectasis and Chronic Pseudomonas aeruginosa Infection. Am J Respir Crit Care Med 2014; 189: 975-982
    CrossrefPubMedGoogle Scholar
  • 13 Kellett F, Redfern J, Niven RM. Evaluation of nebulised hypertonic saline (7%) as an adjunct to physiotherapy in patients with stable bronchiectasis. Respir Med 2005; 99: 27-31
    CrossrefPubMedGoogle Scholar
  • 14 Lopez-Boado YS, Rubin BK. Macrolides as immunomodulatory medications for the therapy of chronic lung diseases. Curr Opin Pharmacol 2008; 8: 286-291
    CrossrefPubMedGoogle Scholar
  • 15 Martinez-Garcia MA, de la Rosa Carrillo D, Soler-Cataluna JJ et al. Prognostic value of bronchiectasis in patients with moderate-to-severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 187: 823-831
    CrossrefPubMedGoogle Scholar
  • 16 McShane PJ, Naureckas ET, Tino G et al. Non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2013; 188: 647-656
    CrossrefPubMedGoogle Scholar
  • 17 Mirsaeidi M, Hadid W, Ericsoussi B et al. Non-tuberculous mycobacterial disease is common in patients with non-cystic fibrosis bronchiectasis. Int J Infect Dis 2013; 17: e1000-4
    CrossrefPubMedGoogle Scholar
  • 18 Mossberg B, Strandberg K, Philipson K et al. Tracheobronchial clearance and beta-adrenoceptor stimulation in patients with chronic bronchitis. Scand J Respir Dis 1976; 57: 281-289
    PubMedGoogle Scholar
  • 19 Murray MP, Govan JR, Doherty CJ et al. A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2011; 183: 491-499
    CrossrefPubMedGoogle Scholar
  • 20 Nair GB, Ilowite JS. Pharmacologic agents for mucus clearance in bronchiectasis. Clin Chest Med 2012; 33: 363-370
    CrossrefPubMedGoogle Scholar
  • 21 Nick JA, Moskowitz SM, Chmiel JF et al. Azithromycin May Antagonize Inhaled Tobramycin When Targeting Pseudomonas aeruginosa in Cystic Fibrosis. Ann Am Thorac Soc 2014; 11: 342-350
    PubMedGoogle Scholar
  • 22 Nicolson CH, Stirling RG, Borg BM et al. The long term effect of inhaled hypertonic saline 6% in non-cystic fibrosis bronchiectasis. Respir Med 2012; 106: 661-667
    CrossrefPubMedGoogle Scholar
  • 23 O'Donnell DE, Webb KA, Bertley JC et al. Mechanisms of relief of exertional breathlessness following unilateral bullectomy and lung volume reduction surgery in emphysema. Chest 1996; 110: 18-27
    CrossrefPubMedGoogle Scholar
  • 24 Pasteur MC, Bilton D, Hill AT et al. British Thoracic Society guideline for non-CF bronchiectasis. Thorax 2010; 65 (Suppl. 01) i1-58
    CrossrefPubMedGoogle Scholar
  • 25 Pasteur MC, Helliwell SM, Houghton SJ et al. An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med 2000; 162: 1277-1284
    CrossrefPubMedGoogle Scholar
  • 26 Rademacher J, Ringshausen FC. Prevention and treatment of exacerbations of non-CF bronchiectasis. European Respiratory Society Monograph 2013; 127-136
    PubMedGoogle Scholar
  • 27 Reeves EP, Molloy K, Pohl K et al. Hypertonic saline in treatment of pulmonary disease in cystic fibrosis. Scientific World Journal 2012; 2012: 465230
    PubMedGoogle Scholar
  • 28 Reeves EP, Williamson M, O'Neill SJ et al. Nebulized hypertonic saline decreases IL-8 in sputum of patients with cystic fibrosis. Am J Respir Crit Care Med 2011; 183: 1517-1523
    CrossrefPubMedGoogle Scholar
  • 29 Seitz AE, Olivier KN, Adjemian J et al. Trends in bronchiectasis among medicare beneficiaries in the United States, 2000 to 2007. Chest 2012; 142: 432-439
    CrossrefPubMedGoogle Scholar
  • 30 Serisier DJ, Bilton D, De Soyza A et al. Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial. Thorax 2013; 68: 812-817
    CrossrefPubMedGoogle Scholar
  • 31 Sexton P, Harrison AC. Susceptibility to nontuberculous mycobacterial lung disease. Eur Respir J 2008; 31: 1322-1333
    CrossrefPubMedGoogle Scholar
  • 32 Sheehan RE, Wells AU, Copley SJ et al. A comparison of serial computed tomography and functional change in bronchiectasis. Eur Respir J 2002; 20: 581-587
    CrossrefPubMedGoogle Scholar
  • 33 Silk HJ, Ambrosino D, Geha RS. Effect of intravenous gammaglobulin therapy in IgG2 deficient and IgG2 sufficient children with recurrent infections and poor response to immunization with Hemophilus influenzae type b capsular polysaccharide antigen. Ann Allergy 1990; 64: 21-25
    PubMedGoogle Scholar
  • 34 Sly PD, Gangell CL, Chen L et al. Risk factors for bronchiectasis in children with cystic fibrosis. N Engl J Med 2013; 368: 1963-1970
    CrossrefPubMedGoogle Scholar
  • 35 Spagnolo P, Fabbri LM, Bush A. Long-term macrolide treatment for chronic respiratory disease. Eur Respir J 2013; 42: 239-251
    CrossrefPubMedGoogle Scholar
  • 36 Svanstrom H, Pasternak B, Hviid A. Cardiovascular risks with azithromycin. N Engl J Med 2013; 369: 580-581
    PubMedGoogle Scholar
  • 37 White L, Mirrani G, Grover M et al. Outcomes of Pseudomonas eradication therapy in patients with non-cystic fibrosis bronchiectasis. Respir Med 2012; 106: 356-360
    CrossrefPubMedGoogle Scholar
  • 38 Wilson R, Hansell DM, Loebinger MR. Definition and aetiology of non-CF bronchiectasis. European Respiratory Society Monograph 2013; 107-119
    PubMedGoogle Scholar
  • 39 Wong C, Jayaram L, Karalus N et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet 2012; 380: 660-667
    CrossrefPubMedGoogle Scholar